Kendle targets Asia with further Indian expansion

By Nick Taylor

- Last updated on GMT

Related tags: India, Clinical trial

Kendle is continuing its efforts to increase its presence outside the US with the establishment of a second office in Ahmedabad in Western India.

The company has had a presence in New Delhi, India since 2004 and has been expanding to allow its clients increased access to the nation’s favourable research conditions.

Asia/Pacific has been targeted by the company as a region that will help it maintain its impressive organic growth in a difficult operating environment.

Candace Kendle, PharmD, Chairman and CEO, said: "Expansion in the Asia/Pacific region, and India in particular, is essential to our continued success as a top global CRO​.

Our increased presence and capacity in the region will allow us to better meet the needs of our customers who are seeking to capitalise on India's cost-effective, yet high-quality clinical research capabilities to develop their compounds​."

By continuing to expand outside of its regional base in New Delhi Kendle has given itself access to a greater proportion of the Indian population, which is one of the big attractions to companies looking to conduct trials in the country.

In addition to easing the recruitment of patients for clinical trials having access to a broad geographic area gives Kendle access to more of the talent pools spread around India.

Ahmedabad has become a focal point for the Indian pharmaceutical industry and multi-nationals looking to set up in the country.

This has been underpinned by the presence of renowned scientific education establishments and Zydus Cadila and Torrent Pharmaceuticals establishing their headquarters in the city.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us


View more